Literature DB >> 20435867

National comparisons of lung cancer survival in England, Norway and Sweden 2001-2004: differences occur early in follow-up.

Lars Holmberg1, Fredrik Sandin, Freddie Bray, Mike Richards, James Spicer, Mats Lambe, Asa Klint, Mick Peake, Trond-Eirik Strand, Karen Linklater, David Robinson, Henrik Møller.   

Abstract

BACKGROUND Countries with a similar expenditure on healthcare within Europe exhibit differences in lung cancer survival. Survival in lung cancer was studied in 2001-2004 in England, Norway and Sweden. METHODS Nationwide cancer registries in England, Norway and Sweden were used to identify 250 828 patients with lung cancer from England, 18 386 from Norway and 24 886 from Sweden diagnosed between 1996 and 2004, after exclusion of patients registered through death certificate only or with missing, zero or negative survival times. 5-Year relative survival was calculated by application of the period approach. The excess mortality between the countries was compared using a Poisson regression model. RESULTS In all subcategories of age, sex and follow-up period, the 5-year survival was lower in England than in Norway and Sweden. The age-standardised survival estimates were 6.5%, 9.3% and 11.3% for men and 8.4%, 13.5% and 15.9% for women in the respective countries in 2001-2004. The difference in excess risk of dying between the countries was predominantly confined to the first year of follow-up. The relative excess risk ratio during the first 3 months of follow-up comparing England with Norway 2001-2004 varied between 1.23 and 1.46, depending on sex and age, and between 1.56 and 1.91 comparing England with Sweden. CONCLUSION Access to healthcare and population awareness are likely to be major reasons for the differences, but it cannot be excluded that diagnostic and therapeutic activity play a role. Future improvements in lung cancer management may be seen early in follow-up.

Entities:  

Mesh:

Year:  2010        PMID: 20435867     DOI: 10.1136/thx.2009.124222

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

1.  Polypsychopharmacy.

Authors:  S Sturges; M Brown
Journal:  Bull Menninger Clin       Date:  1975-05

2.  Pemetrexed plus dendritic cells as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer who had treatment with TKI.

Authors:  Rong-Hang Hu; Sheng-Bin Shi; Jie-Lin Qi; Jing Tian; Xiao-Yong Tang; Guo-Fang Liu; Chun-Xiao Chang
Journal:  Med Oncol       Date:  2014-06-24       Impact factor: 3.064

Review 3.  Lung cancer in symptomatic patients presenting in primary care: a systematic review of risk prediction tools.

Authors:  Mia Schmidt-Hansen; Sabine Berendse; Willie Hamilton; David R Baldwin
Journal:  Br J Gen Pract       Date:  2017-05-08       Impact factor: 5.386

4.  Stereotactic body radiotherapy for stage I non-small cell lung cancer.

Authors:  Ben J Slotman
Journal:  J Radiosurg SBRT       Date:  2011

5.  Clinical implications of fibroblast activation protein-α in non-small cell lung cancer after curative resection: a new predictor for prognosis.

Authors:  Yida Liao; Yang Ni; Ren He; Weidong Liu; Jiajun Du
Journal:  J Cancer Res Clin Oncol       Date:  2013-07-09       Impact factor: 4.553

6.  Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort.

Authors:  Marshall W Pitz; Grace Musto; Srisala Navaratnam
Journal:  Can Respir J       Date:  2013 Jan-Feb       Impact factor: 2.409

7.  Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets.

Authors:  L Elliss-Brookes; S McPhail; A Ives; M Greenslade; J Shelton; S Hiom; M Richards
Journal:  Br J Cancer       Date:  2012-09-20       Impact factor: 7.640

8.  Social differences in lung cancer management and survival in South East England: a cohort study.

Authors:  Anders Berglund; Mats Lambe; Margreet Lüchtenborg; Karen Linklater; Michael D Peake; Lars Holmberg; Henrik Møller
Journal:  BMJ Open       Date:  2012-05-25       Impact factor: 2.692

9.  Characteristics of patients dying within 30 days of diagnosis of breast or colorectal cancer in Scotland, 2003-2007.

Authors:  D H Brewster; D I Clark; D L Stockton; A J Munro; R J C Steele
Journal:  Br J Cancer       Date:  2011-01-04       Impact factor: 7.640

10.  Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals.

Authors:  Richard Wagland; Jackie Ellis; Chris D Bailey; Jemma Haines; Ann Caress; Mari Lloyd Williams; Paul Lorigan; Jaclyn Smith; Carol Tishelman; Richard Booton; Karen Luker; Fiona Blackhall; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2012-01-20       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.